AMANDA MURPHY
Associate Director, Investor Relations & Public Relations, Aegerion Pharmaceuticals
Email: amanda.murphy@aegerion.com
Phone: 857-242-5024
Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy
VANCOUVER, B.C., May 10, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases ("Novelion" or the "Company"), today reported financial results for the first quarter ended March 31, 2018 and provided an overview of business activities.
Aegerion strengthens balance sheet and liquidity, positioning company for ongoing capital structure review
